The Myeloproliferative Disorders Research Consortium (MPD-RC) focuses on the Philadelphia chromosome negative myeloproliferative neoplasms (MPN) including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) and has the following goals 1) Establish a multi-institutional international research group which will coordinate and facilitate basic and clinical research dealing with the cellular and genetic basis of the MPN. 2) Establish a multi-institutional Clinical Consortium to enable uniform, high volume sample collection, storage and distribution. 3) Perform rationally designed clinical trials in patients with MPN at multiple institutions. 4) Maintain an interactive website for MPD Consortium investigators, a sophisticated international tissue bank and an on-line database that will allow for integration of basic and clinical research. This unique interactive relationship between talented basic researchers and clinical scientists will permit the MPD-RC to develop novel clinical treatment programs for MPN and to identify specific biomarkers that will be useful as indicators of therapeutic response and/or risk reduction. This program has six major projects: Project 1: Genetic Basis of Polycythemia Vera, Project Leader: J. T. Prchal;Project 2: A Novel Murine Model for MPN: Pathology and Therapy of NF-E2 Overexpression, Project Leader: H. L. Pahl;Project 3: Animal Models of Polycythemia Vera, Project Leader: J. L. Spivak;Project 4: Mouse Models of Myelofibrosis, Project Leader: A. Migliaccio;Project 5: Abnormal Stem Cell Trafficking in Myelofibrosis, Project Leader: R. Hoffman;Project 6: MPD Clinical Consortium which will pursue clinical trials in PV. ET and PMF, Project Leader: Lewis Silverman. The 6 projects will be supported by 3 cores: Core A, Administrative Core, PI: R. Hoffman;Core B: Biostatistics and Data Management;PI: J. A. Goldberg and Co-PI R. Marchioli;Core C;Tissue Bank, PI: R. Weinberg. These unique interactions between clinical and laboratory investigators which are interwoven within the MPD-RC will ultimately result in improved understanding of the pathobiology of the MPN as provide well improved strategies that will assist in the management of MPN patients.

Public Health Relevance

The MPD-RC is a group of basic and clinical scientists who are experts in a variety of disciplines pertaining to the MPN including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The overall goal of the MPD-RC is to increase our knowledge of the origins of the MPN with the hope of generating the foundation for the development of novel therapeutic strategies for the treatment of MPN patients

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA108671-08
Application #
8722846
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (O1))
Program Officer
Merritt, William D
Project Start
2004-07-01
Project End
2016-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
8
Fiscal Year
2014
Total Cost
$3,221,226
Indirect Cost
$1,677,074
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Wang, Xiaoli; Haylock, David; Hu, Cing Siang et al. (2016) A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells. Blood 127:3398-409
Divoky, Vladimir; Song, Jihyun; Horvathova, Monika et al. (2016) Delayed hemoglobin switching and perinatal neocytolysis in mice with gain-of-function erythropoietin receptor. J Mol Med (Berl) 94:597-608
Spangrude, Gerald J; Lewandowski, Daniel; Martelli, Fabrizio et al. (2016) P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis. Stem Cells 34:67-82
Migliaccio, Anna Rita (2016) To condition or not to condition-That is the question: The evolution of nonmyeloablative conditions for transplantation. Exp Hematol 44:706-12
Lu, Min; Xia, Lijuan; Liu, Yen-Chun et al. (2015) Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. Blood 126:972-82
Wang, Xiaoli; Cho, Sool Yeon; Hu, Cing Siang et al. (2015) C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients. Exp Hematol 43:100-9.e1
Kovacsovics-Bankowski, Magdalena; Kelley, Todd W; Efimova, Olga et al. (2015) Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2(V617F) allelic burden. Exp Hematol Oncol 5:28
Swierczek, S; Lima, L T; Tashi, T et al. (2015) Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms. Leukemia 29:2432-4
Funnell, Alister P W; Prontera, Paolo; Ottaviani, Valentina et al. (2015) 2p15-p16.1 microdeletions encompassing and proximal to BCL11A are associated with elevated HbF in addition to neurologic impairment. Blood 126:89-93
Falchi, Mario; Varricchio, Lilian; Martelli, Fabrizio et al. (2015) Dexamethasone targeted directly to macrophages induces macrophage niches that promote erythroid expansion. Haematologica 100:178-87

Showing the most recent 10 out of 164 publications